Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 2.5% – Still a Buy?

Posted by Stanley Muller on Jun 16th, 2026

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Get Free Report)’s stock price rose 2.5% on Monday . The company traded as high as $4.24 and last traded at $4.15. Approximately 2,982,046 shares traded hands during mid-day trading, an increase of 790% from the average daily volume of 334,921 shares. The stock had previously closed at $4.05.

Analyst Ratings Changes

BCYC has been the subject of a number of analyst reports. Royal Bank Of Canada cut their price objective on shares of Bicycle Therapeutics from $11.00 to $7.00 and set a “sector perform” rating for the company in a research report on Wednesday, March 18th. Citigroup reissued a “market outperform” rating on shares of Bicycle Therapeutics in a research report on Wednesday, June 3rd. Jefferies Financial Group reissued a “buy” rating and issued a $12.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, April 30th. Truist Financial set a $8.00 price objective on shares of Bicycle Therapeutics in a research report on Tuesday, March 17th. Finally, Needham & Company LLC dropped their target price on shares of Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $14.00.

Read Our Latest Report on BCYC

Bicycle Therapeutics Price Performance

The company has a market capitalization of $289.71 million, a price-to-earnings ratio of -1.32 and a beta of 1.54. The stock’s fifty day simple moving average is $4.67 and its two-hundred day simple moving average is $5.61.

Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.25). The firm had revenue of $0.89 million for the quarter, compared to the consensus estimate of $7.50 million. Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%. On average, sell-side analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -2.01 EPS for the current year.

Insider Transactions at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 5,967 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $4.91, for a total value of $29,297.97. Following the completion of the transaction, the chief executive officer owned 613,029 shares in the company, valued at $3,009,972.39. This represents a 0.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 9,992 shares of company stock valued at $49,363. Corporate insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Bicycle Therapeutics

Several large investors have recently made changes to their positions in BCYC. Assetmark Inc. boosted its position in shares of Bicycle Therapeutics by 74.9% during the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after purchasing an additional 1,552 shares in the last quarter. Clearstead Advisors LLC boosted its position in shares of Bicycle Therapeutics by 234.2% during the 4th quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after purchasing an additional 3,262 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Bicycle Therapeutics by 35.5% during the 1st quarter. Royal Bank of Canada now owns 14,470 shares of the company’s stock valued at $67,000 after purchasing an additional 3,788 shares in the last quarter. Brooklyn Investment Group bought a new position in shares of Bicycle Therapeutics during the 4th quarter valued at about $69,000. Finally, Ausdal Financial Partners Inc. bought a new position in shares of Bicycle Therapeutics during the 2nd quarter valued at about $70,000. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

(Get Free Report)

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.